JANXJanux TherapeuticsJANX info
$56.75info-0.14%24h
Global rank4242
Market cap$2.62B
Change 7d-7.12%
YTD Performance431.37%
SP500 benchmarkOutperform
P/E0
P/S0
Revenue$0
Earnings$0
Dividend yield-
Main Sector
Healthcare
Business data

    Janux Therapeutics (JANX) Stock Overview

    Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on proprietary Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms technology to treat patients suffering from cancer. Its lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. The company is also developing a TRACIr costimulatory bispecific product candidate against programmed death-ligand 1 and Cluster of Differentiation 28 designed to improve the anti-tumor activity of T cells. In addition, its PSMA-TRACTr is designed to target PSMA, a protein expressed in prostate cancer tumors and the vasculature of other tumors; EGFR-TRACTr is designed to target EGFR in various cancer types with multiple approved monoclonal antibodies; and TROP2-TRACTr is designed to target TROP2, a clinically validated anti-tumor target for which there is an approved anti-TROP2 antibody-drug conjugate. The company was incorporated in 2017 and is headquartered in San Diego, California.

    JANX Stock Information

    Symbol
    JANX
    Address
    11099 North Torrey Pines RoadLa Jolla, CA 92037United States
    Founded
    -
    Trading hours
    -
    Website
    https://www.januxrx.com
    Country
    πŸ‡ΊπŸ‡Έ United States
    Phone Number
    858 750 4700

    Janux Therapeutics (JANX) Price Chart

    -
    Value:-

    Janux Therapeutics Overview: Key Details and Summary

    Stock data
    2024
    Change
    Price
    $56.75
    N/A
    Market Cap
    $2.62B
    N/A
    Shares Outstanding
    46.17M
    N/A
    Employees
    64.00
    N/A
    logo
    Facebook Icon
    Twitter Icon
    Linkedin Icon
    Β© 2024 Topstocks.org